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A B S T R A C T
Human parvovirus B19 (PVB19) has been frequently identiﬁed as a cause of anemia in immunocompromised
transplanted patients. Rarely the infection correlates with deterioration of the graft function.
Immunomodulatory therapy in PVB19 cases, still not standardised in dose and duration, has been proven to
achieve good clinical results. The clinical presentation depends mainly on the immunological status of the
patient. Here we report an atypical presentation of an acute PVB19 infection in the immediate postoperative
phase after transplantation and aim to raise the recognition of PVB19 as a signiﬁcant human pathogen in the
early post-transplantation period. Additionally, we provide a literature review of clinical presentation and
management of recently published cases.
1. Introduction
Human parvovirus B19 (PVB19) belongs to the Erythrovirus genus
within the Parvoviridae family. It has been identiﬁed as the cause of the
ﬁfth disease in childhood, hydrops fetalis in pregnancy and a cause of
anemia in immunocompromised patients. The clinical presentation of
an acute PVB19 infection depends mainly on the immunological status
of the patient. The symptoms vary between non-speciﬁc ﬂu-like
complaints, haematological disorders and more typical presentations
such as rash and/or rarely arthralgia.
An increasing number of PVB19-associated syndromes after solid
organ transplantation has been reported. Furthermore, severe compli-
cations requiring high-dose intravenous immunoglobulin (IVIG) ther-
apy and a high rate of recurrence have been described. There is
insuﬃcient experience with diagnosis and therapeutic regimes, espe-
cially if a non-typical disease course is present. Here we describe an
interesting case of an atypical clinical presentation of PVB19 infection
early after kidney and pancreas transplantation.
2. Case report
A 44-year old female patient, listed for combined kidney-pancreas
transplantation due to diabetes mellitus type I associated with end
stage renal disease, received a matching organ from a deceased donor.
On admission the patient had no speciﬁc complains, especially
symptoms of an infection were denied. On physical examination there
were no abnormalities except for a skin lesion at the arteriovenous
(AV)-ﬁstula, where an attempt to recanalize the ﬁstula had failed a few
weeks ago. The laboratory tests showed a slight leukocytosis, normo-
cytic normochromic anemia and increased retention parameters, for
which a haemodialysis was performed.
At the same day the patient received combined kidney-pancreas
transplantation and recovered uneventfully after the operation. A triple
immunosuppressive regimen consisting of tacrolimus, mycophenolate
mofetil and prednisolone and an induction therapy with thymoglobulin
was initiated. A moderate therapy associated pancytopenia was re-
ported but no blood products substitution was required. An ultrasound
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examination showed a good perfusion of the transplants and the organ
function was satisfactory. The retention parameters dropped rapidly,
diuresis of up to 200 ml/h was reported and no further haemodialysis
and no insulin substitution was required. After a short intensive care
stay the patient was successfully transferred to a normal ward. Because
of an intermittent tachycardia, a hyperthyroid state was diagnosed and
accordingly suppression therapy was initiated. Before discharge the
Demers-Catheter was removed as no further haemodialysis treatments
were expected.
Two weeks after transplantation the patient developed fever. The
laboratory results showed a signiﬁcant leucocytosis (31.6 Tsd/µl) and a
drop in hemoglobin (from 10.5 to 8.6 g/dl). Blood and urine cultures,
as well as a skin swab test and sampling from the removed Demers-
Catheter remained negative for bacterial colonization. An empiric anti-
infective therapy with a third generation cephalosporin (ceftriaxone)
and a nitroimidazole antibiotic (metronidazole) was initiated according
to a standard protocol. A newly diagnosed cardiac murmur and a
history of a skin lesion on the left shunt arm raised the suspicion of
endocarditis. Both transthoracal and transesophageal echocardiogra-
phy revealed no pathological ﬁndings. An ECG examination showed no
signiﬁcant pathological results. A CT abdomen and chest scan diag-
nosed no clinically relevant ﬁndings except for a mild transplant-
pancreatitis.
Inspite of ongoing antibiotic therapy the patient suﬀered from
another fever attack, dyspnoe and ﬂu-like symptoms. The laboratory
results showed anew peak in the leukocyte count and thrombocytosis.
The antibiotics were paused and a sampling for probable infectious
agent was aimed. On the next day the patient complained about an
acute arthralgia in the right knee and the right small hand joints. The
joints were swollen and painful and the joint movement was compro-
mised. A symptomatic therapy with nonsteroidal anti-inﬂammatory
drugs (NSADs) was initiated. The following days the complains in the
previously aﬀected joints improved signiﬁcantly but now other joints,
the right shoulder and the left knee, were aﬀected. A diagnostic knee
and shoulder joint aspiration was performed. The cytological examina-
tion of the synovial ﬂuid was not enriched in white blood cells (WBC),
no urate or pyrophosphate depositions were noted and it was compa-
tible with rather non-infectious eﬀusions. The microbiological results
from the direct examination as well as the culture sampling were
negative for bacterial colonization. Numerous rheumatological diag-
nostics were performed which did not show pathological ﬁndings.
Under the suspicion of an infectious complication in the early phase
after transplantation and ongoing immunosuppression, an empiric
antibiotic therapy with glycopeptide antibiotic (vancomycin) and
lincosamide antibiotic (clindamycin) was administered. After a few
days the virological examinations showed a serological evidence of a
newly acquired PVB19 infection with a positive IgM status. The anti-
infective therapy was discontinued and since joint symptoms improved
spontaneously over the course of three days no further therapy was
administered and the patient was discharged. On a follow-up visit to
the outpatient clinic the patient reported no symptoms, the laboratory
results including haemoglobin level had completely normalised. The
course of the events is summarised in Table 1. A more detailed
summary of the laboratory course during the hospitalisation is
presented in Suppl. Table 1.
3. Discussion and conclusion
To summarise, we present an atypical case of an acute PVB19
infection immediately after transplantation. The infection was most
likely acquired nosocomially or shortly before hospitalisation, since a
post-mortem analysis of the donor for a PVB19 infection was negative
as well as the negative serological status of the patient herself during
the pretransplant period. Of note, the clinical course and manifestation
of the infection showed no pathognomonic ﬁndings, e.g. typical skin
rash, severe pure red cell aplasia (PRCA) or myocarditis were not
present. This is most likely the result of the immunosuppressive
therapy, in particular due to suppressed T-cell reactions.
An increasing number of human parvovirus B19 (PVB19)-asso-
ciated syndromes have been reported after solid organ transplantation.
Arthralgia seems to be more common in non-immunocompromised
females [1], typically of a migrating character [2] and usually inter-
mittent, since the virus does not cause joint destruction and rarely
leads to chroniﬁcation [3]. PVB19 is frequently diagnosed in haemo-
dialysis patients [4,5] and is a rare but clinically relevant infection
during the post transplantation period. In case of solid organ trans-
plantation inﬂammatory responses are dimmed by immunosuppressive
regiments, leading to an atypical presentation. The diagnosis is
hampered by the altered immunological responses in patients under
immunosuppressive therapy [6] and a direct evidence of the virus
presence is needed. A clinical study of 98 cases by Eid et al. supported
that the clinical presentation varies and is associated with pancytope-
nia, hepatitis, myocarditis and even allograft tissue loss or dysfunction
have been described [7–9]. Still the most common symptom which led
to evaluation for an acute PVB19 infection was anemia [10,11].
There is no speciﬁc antiviral therapy available on the market.
Usually the patients are treated symptomatically and clearance occurs
spontaneously [9]. Severe complications require therapy with high-
dose intravenous immunoglobulins. Further, reduction of T-cell de-
pleting therapy has additional beneﬁcial eﬀect for the outcome of the
infection. Dose regimens and therapy duration are still not optimised.
Recurrent infections are often seen especially after solid organ trans-
plantation [12–14].
In summary, recognition of PVB19 as a signiﬁcant human pathogen
in the post-transplantation period can improve the diagnostic strategy
and lead to a better management of the transplanted patient.
Appendix A. Supplementary material
Supplementary data associated with this article can be found in the
online version at http://dx.doi.org/10.1016/j.tpr.2016.10.001.
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Table 1
Clinical characteristics and course of events in the post-transplantation period of the described case.
Prior to
op
1 day
postop
14 days
postop
18 days
postop
26 days postop 31 days postop 37 days postop
(discharge)
44 days postop (outpatient
check up)
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